LYNCH DANIEL

Director Lynch sold 47,600 shares (47.6K) for $2,866,534.08 at $60.22 avg, reducing stake 36.5%

Daniel Lynch, a director at SpringWorks Therapeutics, executed 2 separate sales on 2025-02-20, totaling 47,600 shares for $2,866,534.08 at a blended average price of $60.22. The sale reduced his holdings by 36.5%, from 130,544 shares to 82,944 shares. The transaction occurred just 10 days after Lynch's prior three sales on 2025-02-10 at the same ticker. SpringWorks remains unprofitable with a quarterly net income of $-53,530,000.00 despite strong recent revenue growth of +3417.3% year-over-year. The current stock price of $56.56 is -5.6% from the 52-week high and the sales were executed near the top of the recent 52-week range ($28.61–$59.93), reflecting prices above current levels. Investors should note the concentrated selling activity within a 10-day window and the substantial reduction in this director's ownership stake in a pre-profitable biotech company.

Director Lynch sells 175,000 shares (57.2% of holdings) for $9.5M across 3 transactions; stock up 60.2% in 30 days

Director Daniel Lynch sold 175,000 shares in three separate transactions at prices ranging from $53.23 to $55.51, reducing his stake from 305,944 shares to 130,944 shares. The magnitude is substantial: this represents a 57.2% reduction in his holdings and $9,530,351.22 in proceeds. The timing context is noteworthy—the stock has appreciated 60.2% over the past 30 days and 62.2% over the past 90 days, trading at its 52-week high of $59.28. Lynch's blended sale price of $54.46 sits below the current price, indicating the sales occurred earlier in or concurrent with the recent rally. Against this backdrop, the company remains unprofitable, with the latest quarter showing net income of $-53,530,000.00 despite revenues of $49,301,000.00. The large percentage reduction in holdings by a director during a strong uptrend, combined with the company's negative profitability metrics, merits attention to understand the rationale.